BeOne Medicines (NASDAQ:ONC) SVP Sells $580,203.20 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 1,660 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $349.52, for a total transaction of $580,203.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, January 7th, Chan Henry Lee sold 664 shares of BeOne Medicines stock. The stock was sold at an average price of $331.76, for a total value of $220,288.64.
• On Thursday, December 11th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The shares were sold at an average price of $325.00, for a total value of $107,900.00.
• On Wednesday, November 12th, Chan Henry Lee sold 996 shares of BeOne Medicines stock. The stock was sold at an average price of $349.17, for a total transaction of $347,773.32.

BeOne Medicines Trading Up 2.0%

Shares of ONC stock opened at $353.92 on Monday. The company has a market capitalization of $38.81 billion, a PE ratio of 693.96 and a beta of 0.52. The firm has a 50 day moving average price of $327.94 and a two-hundred day moving average price of $325.35. The company has a quick ratio of 2.17, a current ratio of 2.39 and a debt-to-equity ratio of 0.03. BeOne Medicines Ltd. – Sponsored ADR has a 12-month low of $196.45 and a 12-month high of $385.22.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ONC shares. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of BeOne Medicines in a report on Wednesday, December 17th. Barclays raised their price objective on BeOne Medicines from $385.00 to $394.00 and gave the company an “overweight” rating in a research note on Wednesday. Citizens Jmp raised their target price on shares of BeOne Medicines from $348.00 to $396.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Zacks Research lowered BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 28th. Finally, Citigroup boosted their price objective on shares of BeOne Medicines from $399.00 to $405.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $379.07.

Hedge Funds Weigh In On BeOne Medicines

Several institutional investors have recently made changes to their positions in the stock. Primecap Management Co. CA bought a new stake in BeOne Medicines in the 2nd quarter valued at about $1,231,720,000. Capital International Investors boosted its holdings in BeOne Medicines by 3.3% during the 3rd quarter. Capital International Investors now owns 5,046,058 shares of the company’s stock worth $1,716,883,000 after acquiring an additional 161,052 shares during the last quarter. Temasek Holdings Private Ltd purchased a new position in BeOne Medicines during the second quarter worth about $244,603,000. Marshall Wace LLP bought a new position in shares of BeOne Medicines during the 2nd quarter worth approximately $113,190,000. Finally, Bank of America Corp DE lifted its holdings in BeOne Medicines by 23.5% during the third quarter. Bank of America Corp DE now owns 345,256 shares of the company’s stock worth $117,629,000 after acquiring an additional 65,763 shares during the period. Institutional investors and hedge funds own 48.55% of the company’s stock.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.